Cargando…

An integrated epidemiological and neural net model of the warfarin effect in managed care patients

INTRODUCTION: Risk assessment tools are utilized to estimate the risk for stroke and need of anticoagulation therapy for patients with atrial fibrillation (AF). These risk stratification scores are limited by the information inputted into them and a reliance on time-independent variables. The object...

Descripción completa

Detalles Bibliográficos
Autores principales: Jacobs, David M, Stefanovic, Filip, Wilton, Greg, Gomez-Caminero, Andres, Schentag, Jerome J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5441673/
https://www.ncbi.nlm.nih.gov/pubmed/28572740
http://dx.doi.org/10.2147/CPAA.S136243
_version_ 1783238304409321472
author Jacobs, David M
Stefanovic, Filip
Wilton, Greg
Gomez-Caminero, Andres
Schentag, Jerome J
author_facet Jacobs, David M
Stefanovic, Filip
Wilton, Greg
Gomez-Caminero, Andres
Schentag, Jerome J
author_sort Jacobs, David M
collection PubMed
description INTRODUCTION: Risk assessment tools are utilized to estimate the risk for stroke and need of anticoagulation therapy for patients with atrial fibrillation (AF). These risk stratification scores are limited by the information inputted into them and a reliance on time-independent variables. The objective of this study was to develop a time-dependent neural net model to identify AF populations at high risk of poor clinical outcomes and evaluate the discriminatory ability of the model in a managed care population. METHODS: We performed a longitudinal, cohort study within a health-maintenance organization from 1997 to 2008. Participants were identified with incident AF irrespective of warfarin status and followed through their duration within the database. Three clinical outcome measures were evaluated including stroke, myocardial infarction, and hemorrhage. A neural net model was developed to identify patients at high risk of clinical events and defined to be an “enriched” patient. The model defines the enrichment based on the top 10 minimum mean square error output parameters that describe the three clinical outcomes. Cox proportional hazard models were utilized to evaluate the outcome measures. RESULTS: Among 285 patients, the mean age was 74±12 years with a mean follow-up of 4.3±2.6 years, and 154 (54%) were treated with warfarin. After propensity score adjustment, warfarin use was associated with a slightly increased risk of adverse outcomes (including stroke, myocardial infarction, and hemorrhage), though it did not attain statistical significance (adjusted hazard ratio [aHR] =1.22; 95% confidence interval [CI] 0.75–1.97; p=0.42). Within the neural net model, subjects at high risk of adverse outcomes were identified and labeled as “enriched.” Following propensity score adjustment, enriched subjects were associated with an 81% higher risk of adverse outcomes as compared to nonenriched subjects (aHR=1.81; 95% CI, 1.15–2.88; p=0.01). CONCLUSION: Enrichment methodology improves the statistical discrimination of meaningful endpoints when used in a health records-based analysis.
format Online
Article
Text
id pubmed-5441673
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-54416732017-06-01 An integrated epidemiological and neural net model of the warfarin effect in managed care patients Jacobs, David M Stefanovic, Filip Wilton, Greg Gomez-Caminero, Andres Schentag, Jerome J Clin Pharmacol Original Research INTRODUCTION: Risk assessment tools are utilized to estimate the risk for stroke and need of anticoagulation therapy for patients with atrial fibrillation (AF). These risk stratification scores are limited by the information inputted into them and a reliance on time-independent variables. The objective of this study was to develop a time-dependent neural net model to identify AF populations at high risk of poor clinical outcomes and evaluate the discriminatory ability of the model in a managed care population. METHODS: We performed a longitudinal, cohort study within a health-maintenance organization from 1997 to 2008. Participants were identified with incident AF irrespective of warfarin status and followed through their duration within the database. Three clinical outcome measures were evaluated including stroke, myocardial infarction, and hemorrhage. A neural net model was developed to identify patients at high risk of clinical events and defined to be an “enriched” patient. The model defines the enrichment based on the top 10 minimum mean square error output parameters that describe the three clinical outcomes. Cox proportional hazard models were utilized to evaluate the outcome measures. RESULTS: Among 285 patients, the mean age was 74±12 years with a mean follow-up of 4.3±2.6 years, and 154 (54%) were treated with warfarin. After propensity score adjustment, warfarin use was associated with a slightly increased risk of adverse outcomes (including stroke, myocardial infarction, and hemorrhage), though it did not attain statistical significance (adjusted hazard ratio [aHR] =1.22; 95% confidence interval [CI] 0.75–1.97; p=0.42). Within the neural net model, subjects at high risk of adverse outcomes were identified and labeled as “enriched.” Following propensity score adjustment, enriched subjects were associated with an 81% higher risk of adverse outcomes as compared to nonenriched subjects (aHR=1.81; 95% CI, 1.15–2.88; p=0.01). CONCLUSION: Enrichment methodology improves the statistical discrimination of meaningful endpoints when used in a health records-based analysis. Dove Medical Press 2017-05-18 /pmc/articles/PMC5441673/ /pubmed/28572740 http://dx.doi.org/10.2147/CPAA.S136243 Text en © 2017 Jacobs et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Jacobs, David M
Stefanovic, Filip
Wilton, Greg
Gomez-Caminero, Andres
Schentag, Jerome J
An integrated epidemiological and neural net model of the warfarin effect in managed care patients
title An integrated epidemiological and neural net model of the warfarin effect in managed care patients
title_full An integrated epidemiological and neural net model of the warfarin effect in managed care patients
title_fullStr An integrated epidemiological and neural net model of the warfarin effect in managed care patients
title_full_unstemmed An integrated epidemiological and neural net model of the warfarin effect in managed care patients
title_short An integrated epidemiological and neural net model of the warfarin effect in managed care patients
title_sort integrated epidemiological and neural net model of the warfarin effect in managed care patients
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5441673/
https://www.ncbi.nlm.nih.gov/pubmed/28572740
http://dx.doi.org/10.2147/CPAA.S136243
work_keys_str_mv AT jacobsdavidm anintegratedepidemiologicalandneuralnetmodelofthewarfarineffectinmanagedcarepatients
AT stefanovicfilip anintegratedepidemiologicalandneuralnetmodelofthewarfarineffectinmanagedcarepatients
AT wiltongreg anintegratedepidemiologicalandneuralnetmodelofthewarfarineffectinmanagedcarepatients
AT gomezcamineroandres anintegratedepidemiologicalandneuralnetmodelofthewarfarineffectinmanagedcarepatients
AT schentagjeromej anintegratedepidemiologicalandneuralnetmodelofthewarfarineffectinmanagedcarepatients
AT jacobsdavidm integratedepidemiologicalandneuralnetmodelofthewarfarineffectinmanagedcarepatients
AT stefanovicfilip integratedepidemiologicalandneuralnetmodelofthewarfarineffectinmanagedcarepatients
AT wiltongreg integratedepidemiologicalandneuralnetmodelofthewarfarineffectinmanagedcarepatients
AT gomezcamineroandres integratedepidemiologicalandneuralnetmodelofthewarfarineffectinmanagedcarepatients
AT schentagjeromej integratedepidemiologicalandneuralnetmodelofthewarfarineffectinmanagedcarepatients